<?xml version="1.0" encoding="UTF-8"?>
<p id="p0130">In the absence of a specific antiviral drug, anecdotal use of drugs like lopinavir, ritonavir, interferon-1Î², RNA polymerase inhibitor remdesivir, and chloroquine has been reported. 2019-nCoV receptor binding site has a strong affinity with angiotensin converting enzyme 2 (ACE2) and inhibitors of the rennin angiotensin system may have a role in treating severe respiratory disease [
 <xref rid="bib13" ref-type="bibr">13</xref>,
 <xref rid="bib14" ref-type="bibr">14</xref>]. Zinc nanoparticles were shown to have inhibitory effects on H1N1 viral load, though their effect in COVID-19 is unknown and untested [
 <xref rid="bib15" ref-type="bibr">15</xref>]. Vitamin C supplementation has some role in prevention of pneumonia and its effect on COVID-19 needs evaluation [
 <xref rid="bib16" ref-type="bibr">16</xref>]. Efforts to develop a vaccine are underway, which will be a major tool to contain this epidemic [
 <xref rid="bib17" ref-type="bibr">17</xref>].
</p>
